This hypothesis was confirmed in two phase II clinical trials in EGFR-mutant NSCLC treatment-naïve patients, the randomized Japanese (JO25567) trial comparing erlotinib plus bevacizumab vs. erlotinib alone, and the single-arm Caucasian (BELIEF) trial. Here, EGFR is linked to non-small cell lung carcinoma.